Return to content in this issue

 

Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience

Loli-Ausejo D1,2*, Perdomo G3*, Mascaró B1,2, Martínez-Olondris P2,4, Sánchez-Fernández MC1, Mullol J2,5,6,7, Valero A1,2,6,7, Arismendi E2,4,6,7**, Bobolea I1,2,6,7**

1Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain
2Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain
3Department of Allergy, Hospital Santa Creu i Sant Pau, Barcelona, Spain
4Department of Pneumology, Hospital Clínic Barcelona, Barcelona, Spain
5Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, Barcelona, Spain
6University of Barcelona, Barcelona, Spain
7CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
*These authors contributed equally to this work.
**These authors contributed equally to this work and share senior authorship.

J Investig Allergol Clin Immunol 2023; Vol 33(3) : 209-210
doi: 10.18176/jiaci.0898

Key words: Asthma, Severe eosinophilic asthma, Mepolizumab, Monoclonal antibodies, Treatment